Anavex Life Sciences Corp (AVXL)

[crescentmotor]

This is in great contrast to $AVXL with multiple readouts on deck.

That's the big distinction between the two companies. SAVA is a one-trick pony drug wise and, so far, is only targeting AD. AVXL has a diverse pipeline disease indication wise with Rett possibly being a huge near-term winner. For AVXL to remain ahead in the AD race, it will have to receive AA. If not, and additional trials are required, SAVA will leap ahead timewise because it will complete its large RETHINK trial around this time next year and its REFOCUS trial around mid 2025. I own both companies--exciting times to own both over the next couple of years.